Ask AI

Capsule Summaries

Share

Program Content

Activities

  • 2L Pirtobrutinib
    Pirtobrutinib as 2L Therapy for CLL/SLL Following  cBTKi Therapy: Pooled Analysis of BRUIN LOXO-BTK18001 and BRUIN CLL-321
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2025

  • BRUIN CLL-314
    BRUIN CLL-314: Pirtobrutinib vs Ibrutinib in Treatment-Naive and BTKi-Naive R/R CLL/SLL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2025

  • CaDAnCe 101
    CaDAnCe-101 Update: Phase I Study Evaluating BTK Degrader BGB-16673 in R/R CLL/SLL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2025

  • BRUIN Update
    BRUIN: Final Update From Phase I/II Trial of Pirtobrutinib for CLL/SLL Previously Treated With a Covalent BTKi
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2025

  • ALPINE Long Term Extension
    Phase III ALPINE Long-Term Extension Study of Zanabrutinib in Patients With Relapsed or Refractory CLL/SLL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2025

  • Bexobrutideg in RR CLL
    Phase Ia/b Trial of Bexobrutideg, a BTK Degrader, in Adults With Relapsed/Refractory CLL/SLL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Lilly.

Lilly